{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:04:42Z","timestamp":1794287082202,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIHR School for Primary Care Research (SPCR), grant reference number: 622","id":[{"id":"https:\/\/ror.org\/03wz10q85","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1\u201342 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1. In 12-17-year-olds, we estimated 3 (95%CI 0\u20135) and 5 (95%CI 3\u20136) additional cases of myocarditis per million following a first and second dose with BNT162b2, respectively. An additional 12 (95%CI 0\u201323) hospitalisations with epilepsy and 4 (95%CI 0\u20136) with demyelinating disease (in females only, mainly optic neuritis) were estimated per million following a second dose with BNT162b2. SARS-CoV-2 infection was associated with increased risks of hospitalisation from seven outcomes including multisystem inflammatory syndrome and myocarditis, but these risks were largely absent in those vaccinated prior to infection. We report a favourable safety profile of COVID-19 vaccination in under-18s.<\/jats:p>","DOI":"10.1038\/s41467-024-47745-z","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T06:01:49Z","timestamp":1716789709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-5241","authenticated-orcid":false,"given":"Emma","family":"Copland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Patone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2414-2906","authenticated-orcid":false,"given":"Defne","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahiru","family":"Handunnetthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-0207","authenticated-orcid":false,"given":"David P. J.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-7991","authenticated-orcid":false,"given":"Nicholas L.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-1967","authenticated-orcid":false,"given":"Paul","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-3056","authenticated-orcid":false,"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A. C.","family":"Coupland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Harnden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6848-5241","authenticated-orcid":false,"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-7283","authenticated-orcid":false,"given":"Julia","family":"Hippisley-Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"47745_CR1","unstructured":"Health Policy Team. COVID-19 vaccination for children and young people. in Royal College of Paediatrics and Child Health, 2023 (2023)."},{"key":"47745_CR2","unstructured":"UK Health Security Agency. Week 19 report (up to week 18 data): 11 May 2023. in Weekly National Influenza and COVID-19 surveillance report (2023)."},{"key":"47745_CR3","unstructured":"UK Health Security Agency. COVID-19: the green book, chapter 14a. (2020)."},{"key":"47745_CR4","unstructured":"Department of Health and Social Care. JCVI statement on the COVID-19 vaccination programme for 2023: 8 November 2022. 2023 (2023)."},{"key":"47745_CR5","doi-asserted-by":"publisher","first-page":"n1931","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox, J. et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ 374, n1931 (2021).","journal-title":"BMJ"},{"key":"47745_CR6","first-page":"12","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27, 12 (2021).","journal-title":"Nat. Med."},{"key":"47745_CR7","first-page":"2","volume":"28","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat. Med. 28, 2 (2021).","journal-title":"Nat. Med."},{"key":"47745_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.122.059970","volume":"146","author":"M Patone","year":"2022","unstructured":"Patone, M. et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation 146, 743\u2013754 (2022).","journal-title":"Circulation"},{"key":"47745_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck","year":"2021","unstructured":"Frenck, R. W. et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N. Engl. J. Med. 385, 239\u2013250 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47745_CR10","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","volume":"385","author":"K Ali","year":"2021","unstructured":"Ali, K. et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N. Engl. J. Med. 385, 2241\u20132251 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47745_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N. Engl. J. Med. 385, 1078\u20131090 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47745_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0140-6736(22)01185-0","volume":"400","author":"C Sacco","year":"2022","unstructured":"Sacco, C. et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5\u201311 years in Italy: a retrospective analysis of January\u2013April, 2022. Lancet 400, 97\u2013103 (2022).","journal-title":"Lancet"},{"key":"47745_CR13","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S2352-4642(22)00100-6","volume":"6","author":"U Nygaard","year":"2022","unstructured":"Nygaard, U. et al. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc. Health 6, 459\u2013465 (2022).","journal-title":"Lancet Child Adolesc. Health"},{"key":"47745_CR14","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.15585\/mmwr.mm7035e5","volume":"70","author":"TK Boehmer","year":"2021","unstructured":"Boehmer, T. K. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. MMWR Morb. Mortal. Wkly Rep. 70, 1228\u20131232 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"47745_CR15","doi-asserted-by":"crossref","unstructured":"Molloy, E. J., Nakra, N., Gale, C., Dimitriades, V. R. & Lakshminrusimha, S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. Pediatr. Res. 93, 1499\u20131508 (2023).","DOI":"10.1038\/s41390-022-02263-w"},{"key":"47745_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"47745_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13495-5","volume":"12","author":"S Lopez-Leon","year":"2022","unstructured":"Lopez-Leon, S. et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci. Rep. 12, 9950 (2022).","journal-title":"Sci. Rep."},{"key":"47745_CR18","doi-asserted-by":"crossref","unstructured":"Clayton, C., Clayton, R., Al-Azri, S., Mogeh, I. & Potter, M. Understanding parental hesitancy toward children\u2019s COVID-19 vaccinations: The influence of government, media and interpersonal communication. Front. Commun. 7, 1004139 (2023).","DOI":"10.3389\/fcomm.2022.1004139"},{"key":"47745_CR19","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1016\/j.vaccine.2022.08.073","volume":"40","author":"R Ceannt","year":"2022","unstructured":"Ceannt, R., Vallieres, F., Burns, H., Murphy, J. & Hyland, P. Covid-19 vaccine hesitancy and resistance amongst parents of children under 18 years of age in Ireland. Vaccine 40, 6196\u20136200 (2022).","journal-title":"Vaccine"},{"key":"47745_CR20","doi-asserted-by":"publisher","first-page":"7789","DOI":"10.1016\/j.vaccine.2020.10.027","volume":"38","author":"S Bell","year":"2020","unstructured":"Bell, S., Clarke, R., Mounier-Jack, S., Walker, J. L. & Paterson, P. Parents\u2019 and guardians\u2019 views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine 38, 7789\u20137798 (2020).","journal-title":"Vaccine"},{"key":"47745_CR21","unstructured":"World Health Organization. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know (2022)."},{"key":"47745_CR22","unstructured":"World Health Organization. The Moderna COVID-19 (mRNA-1273) vaccine: what you need to know. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know (2022)."},{"key":"47745_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2109730","volume":"385","author":"D Mevorach","year":"2021","unstructured":"Mevorach, D. et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N. Engl. J. Med. 385, 23 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47745_CR24","doi-asserted-by":"crossref","unstructured":"Li, M. et al. Myocarditis or Pericarditis Following the COVID-19 Vaccination in Adolescents: A Systematic Review. Vaccines 10, 1316 (2022).","DOI":"10.3390\/vaccines10081316"},{"key":"47745_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/M22-2274","volume":"175","author":"K Goddard","year":"2022","unstructured":"Goddard, K. et al. Incidence of Myocarditis\/Pericarditis Following mRNA COVID-19 Vaccination Among Children and Younger Adults in the United States. Ann. Intern Med. 175, 11 (2022).","journal-title":"Ann. Intern Med."},{"key":"47745_CR26","doi-asserted-by":"crossref","unstructured":"Cheng, D. R. et al. Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12\u201317-year olds in Victoria, Australia. BMJ Paediatr. Open 6, e001472 (2022).","DOI":"10.1136\/bmjpo-2022-001472"},{"key":"47745_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S2213-2600(22)00059-5","volume":"10","author":"RR Ling","year":"2022","unstructured":"Ling, R. R. et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir. Med. 10, 679\u2013688 (2022).","journal-title":"Lancet Respir. Med."},{"key":"47745_CR28","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1056\/NEJMc2207270","volume":"387","author":"G Witberg","year":"2022","unstructured":"Witberg, G. et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. N. Engl. J. Med. 387, 1816\u20131817 (2022).","journal-title":"N. Engl. J. Med."},{"key":"47745_CR29","doi-asserted-by":"publisher","first-page":"e13759","DOI":"10.1111\/eci.13759","volume":"52","author":"A Krug","year":"2022","unstructured":"Krug, A., Stevenson, J. & H\u00f8eg, T. B. BNT162b2 Vaccine-Associated Myo\/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis. Eur. J. Clin. Investig. 52, e13759 (2022).","journal-title":"Eur. J. Clin. Investig."},{"key":"47745_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamapediatrics.2022.6166","volume":"177","author":"SA Buchan","year":"2023","unstructured":"Buchan, S. A. et al. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. JAMA Pediatrics 177, 410\u2013418 (2023).","journal-title":"JAMA Pediatrics"},{"key":"47745_CR31","doi-asserted-by":"publisher","first-page":"e000373","DOI":"10.1136\/bmjmed-2022-000373","volume":"2","author":"A Husby","year":"2023","unstructured":"Husby, A. et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. BMJ Med. 2, e000373 (2023).","journal-title":"BMJ Med."},{"key":"47745_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1001\/jamapediatrics.2023.1440","volume":"177","author":"M Hu","year":"2023","unstructured":"Hu, M. et al. Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years. JAMA Pediatrics 177, 7 (2023).","journal-title":"JAMA Pediatrics"},{"key":"47745_CR33","doi-asserted-by":"crossref","unstructured":"Watanabe, A. et al. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. JAMA Pediatr. 177, 384\u2013394 (2023).","DOI":"10.1001\/jamapediatrics.2022.6243"},{"key":"47745_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.vaccine.2022.10.079","volume":"41","author":"DE Malden","year":"2023","unstructured":"Malden, D. E. et al. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system. Vaccine 41, 315\u2013322 (2023).","journal-title":"Vaccine"},{"key":"47745_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.15585\/mmwr.mm7202a5","volume":"72","author":"AM Hause","year":"2023","unstructured":"Hause, A. M. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. MMWR Morb. Mortal. Wkly Rep. 72, 39\u201343 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"47745_CR36","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ 354, i4515 (2016).","journal-title":"BMJ"},{"key":"47745_CR37","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/oxfordjournals.aje.a008695","volume":"143","author":"CP Farrington","year":"1996","unstructured":"Farrington, C. P., Nash, J. & Miller, E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am. J. Epidemiol. 143, 1165\u20131173 (1996).","journal-title":"Am. J. Epidemiol."},{"key":"47745_CR38","doi-asserted-by":"publisher","first-page":"e247176","DOI":"10.1136\/bcr-2021-247176","volume":"15","author":"Z Wangu","year":"2022","unstructured":"Wangu, Z., Swartz, H. & Doherty, M. Multisystem inflammatory syndrome in children (MIS-C) possibly secondary to COVID-19 mRNA vaccination. BMJ Case Rep. 15, e247176 (2022).","journal-title":"BMJ Case Rep."},{"key":"47745_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/bloodadvances.2021006379","volume":"6","author":"C Visser","year":"2022","unstructured":"Visser, C. et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv. 6, 1637\u20131644 (2022).","journal-title":"Blood Adv."},{"key":"47745_CR40","doi-asserted-by":"publisher","first-page":"108822","DOI":"10.1016\/j.yebeh.2022.108822","volume":"134","author":"K Lin","year":"2022","unstructured":"Lin, K. et al. Should patients with epilepsy be vaccinated against coronavirus disease 2019? A systematic review and meta-analysis. Epilepsy Behav. 134, 108822 (2022).","journal-title":"Epilepsy Behav."},{"key":"47745_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/00099228211067678","volume":"61","author":"RK Kalra","year":"2022","unstructured":"Kalra, R. K., Jayadeep, S. & Ball, A. L. Acute Pancreatitis in an Adolescent Following COVID Vaccination. Clin. Pediatrics 61, 236\u2013240 (2022).","journal-title":"Clin. Pediatrics"},{"key":"47745_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jocn.2023.03.008","volume":"111","author":"F Nabizadeh","year":"2023","unstructured":"Nabizadeh, F., Noori, M., Rahmani, S. & Hosseini, H. Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review. J. Clin. Neurosci. 111, 57\u201370 (2023).","journal-title":"J. Clin. Neurosci."},{"key":"47745_CR43","doi-asserted-by":"publisher","first-page":"e245455","DOI":"10.1136\/bcr-2021-245455","volume":"15","author":"S Kanou","year":"2022","unstructured":"Kanou, S., Wardeh, L., Govindarajan, S. & Macnay, K. Guillain-Barre syndrome (GBS) associated with COVID-19 infection that resolved without treatment in a child. BMJ Case Rep. 15, e245455 (2022).","journal-title":"BMJ Case Rep."},{"key":"47745_CR44","unstructured":"Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document: Pfizer-BioNTech COVID-19 Vaccine. (2020)."},{"key":"47745_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12026-023-09368-2","volume":"71","author":"V Syrmou","year":"2023","unstructured":"Syrmou, V. et al. COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report. Immunologic Res. 71, 4 (2023).","journal-title":"Immunologic Res."},{"key":"47745_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4168\/aair.2021.13.4.526","volume":"13","author":"MA Kim","year":"2021","unstructured":"Kim, M. A. et al. COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria\/Angioedema\/Anaphylaxis Working Group. Allergy Asthma Immunol. Res 13, 526\u2013544 (2021).","journal-title":"Allergy Asthma Immunol. Res"},{"key":"47745_CR47","unstructured":"National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. (2022)."},{"key":"47745_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2022.11.018","volume":"140","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Safety and Tolerability of COVID-19 Vaccine in Children With Epilepsy: A Prospective, Multicenter Study. Pediatr. Neurol. 140, 3\u20138 (2023).","journal-title":"Pediatr. Neurol."},{"key":"47745_CR49","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/epi.17250","volume":"63","author":"V Hood","year":"2022","unstructured":"Hood, V. et al. COVID-19 vaccine in patients with Dravet syndrome: Observations and real-world experiences. Epilepsia 63, 1778\u20131786 (2022).","journal-title":"Epilepsia"},{"key":"47745_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10072-021-05662-9","volume":"43","author":"RK Garg","year":"2022","unstructured":"Garg, R. K. & Paliwal, V. K. Spectrum of neurological complications following COVID-19 vaccination. Neurological Sci. 43, 3\u201340 (2022).","journal-title":"Neurological Sci."},{"key":"47745_CR51","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","volume":"362","author":"II Ismail","year":"2022","unstructured":"Ismail, I. I. & Salama, S. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J. Neuroimmunol. 362, 577765 (2022).","journal-title":"J. Neuroimmunol."},{"key":"47745_CR52","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/bjophthalmol-2016-309978","volume":"102","author":"D Averseng-Peaureaux","year":"2018","unstructured":"Averseng-Peaureaux, D. et al. Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. Br. J. Ophthalmol. 102, 808\u2013813 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"47745_CR53","unstructured":"Department of Health and Social Care. Use of the AstraZeneca COVID-19 (AZD1222) vaccine: updated JCVI statement, 7 May 2021. https:\/\/www.gov.uk\/government\/publications\/use-of-the-astrazeneca-covid-19-vaccine-jcvi-statement-7-may-2021 (2021)."},{"key":"47745_CR54","first-page":"100122","volume":"9","author":"J Mitchell","year":"2021","unstructured":"Mitchell, J. & Yue, Q.-Y. Appendicitis as a possible safety signal for the COVID-19 vaccines. Vaccine: X 9, 100122 (2021).","journal-title":"Vaccine: X"},{"key":"47745_CR55","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamainternmed.2022.1222","volume":"182","author":"H Kildegaard","year":"2022","unstructured":"Kildegaard, H. et al. Risk of Appendicitis After mRNA COVID-19 Vaccination in a Danish Population. JAMA Intern. Med. 182, 684\u2013686 (2022).","journal-title":"JAMA Intern. Med."},{"key":"47745_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36494-0","volume":"14","author":"V Nafilyan","year":"2023","unstructured":"Nafilyan, V. et al. Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Nat. Commun. 14, 1541 (2023).","journal-title":"Nat. Commun."},{"key":"47745_CR57","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1093\/cid\/ciac553","volume":"76","author":"JM Cohen","year":"2022","unstructured":"Cohen, J. M., Carter, M. J., Cheung, C. R. & Ladhani, S., Group, f.t.E.P.I.M.S.T.r.t.S.-C.-S. Lower Risk of Multisystem Inflammatory Syndrome in Children With the Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2. Clin. Infect. Dis. 76, e518\u2013e521 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"47745_CR58","unstructured":"Center for Biologics Evaluation and Research. BEST Initiative. COVID-19 vaccine safety surveillance: protocol addendum for near real-time surveillance of COVID-19 vaccines in the pediatric population. (2022)."},{"key":"47745_CR59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/pds.3337","volume":"22","author":"K Wilson","year":"2013","unstructured":"Wilson, K. & Hawken, S. Drug safety studies and measures of effect using the self-controlled case series design. Pharmacoepidemiol Drug Saf. 22, 108\u2013110 (2013).","journal-title":"Pharmacoepidemiol Drug Saf."}],"updated-by":[{"DOI":"10.1038\/s41467-024-50151-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47745-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47745-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47745-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T03:04:27Z","timestamp":1720494267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-47745-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["47745"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-47745-z","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"17 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-50151-0","URL":"https:\/\/doi.org\/10.1038\/s41467-024-50151-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.H.C. reports grants from National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK and Oxford Wellcome Institutional Strategic Support Fund and other research councils, during the conduct of the study outside the scope of this work. J.H.C. is founder and was shareholder until 9 Aug 2023 of ClinRisk Ltd, which produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. J.H.C. is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work and is a consultant for Endeavour Predict Ltd outside this work. A.S. serves on a number of UK and Scottish Government COVID-19 advisory groups and was a member of AstraZeneca\u2019s Thrombotic Thrombocytopenic Taskforce; all roles are unremunerated. A.H. is Deputy Chair of the Joint Committee on Vaccination and Immunisation. D.H. serves on the UK Government Commission on Human Medicines P.M. has received speaker and advisory board fees from Moderna and Astra Zeneca. All other authors declare no competing interests related to this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3822"}}